The use of TANGO antisense oligonucleotide-based technology, developed by Stoke Therapeutics, resulted in a dose-dependent increase in brain levels of the NaV1.1 protein that is deficient in Dravet syndrome, a mouse study has shown.  This technology can potentially treat the underlying genetic cause of any disease caused by mutations in a single gene.  Based on these TANGO findings, the company currently is enrolling children and adolescents with Dravet syndrome in its Phase 1/2a MONARCH clinical…

You must be logged in to read/download the full post.